Fig. 3
From: Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
Survival analysis for NTRK mutant patients received ICIs in OAK/ POPLAR cohorts. A: Survival curves for patients with or without NTRK mutation receiving ICIs treatment. B: Survival curves of NSCLC patients in the bTMB-low group. C: Survival curves of NSCLC patients in the bTMB-high group. D-F: Survival curves for patients with or without NTRK1/2/3 mutation receiving ICIs treatment. G-I: Survival curves of subgroup analysis in NSCLC patients with high-bTMB.